Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Set to Submit Bill to Lift Ban on Cannabis-Derived Drugs
October 11, 2023
- Japan Panel to Review Label Expansions for Opdivo, Adcetris, and More on Oct. 23
October 10, 2023
- Many Back Expansion in Range of CEA Price Tweaks for Pricey Drugs: Chuikyo
October 5, 2023
- Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
- WHO Recommends Takeda’s Dengue Vaccine in Children Ages 6-16
October 4, 2023
- MHLW Set to Wrap Up Drug Copay Debate by Year-End: Minister
October 4, 2023
- NHO Data Now Available through PMDA’s MID-NET Database
October 3, 2023
- As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
October 2, 2023
- Japan Seeking Solutions as Lab Monkey Shortage, Price Surge Threaten to Stymie Drug Development
October 2, 2023
- MHLW Proposes Setting Key Drugs as Category Separated from Bundled Trades
September 29, 2023
- Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
- MHLW Expert Panel Draws Up New Cancer Research Strategy
September 28, 2023
- As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access
September 28, 2023
- Japan PM Asks Health Minister to Reform Pricing of Potential Blockbusters
September 28, 2023
- Ex-Senior Vice Minister Koga to Lead LDP’s Health Division
September 28, 2023
- Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
- Kamoshita Tapped as Advisor to PM on Drug, Dementia Policies
September 27, 2023
- Aichi Case of Death After COVID Shot Could Have Been Avoided with Adequate Steps: Report
September 27, 2023
- Japan to Balance Innovation, Finances in Leqembi Pricing: Minister
September 27, 2023
- Draft Revision of Basic Blood Product Policy OK’ed, to Be Finalized by March-End
September 27, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…